Healthcare enforcement
PBM Transparency Moves From Reform Proposal to Pricing Design
Optum Rx’s fee-based PBM model adds market context to DOL’s proposed PBM fee-disclosure rule and the broader push for compensation transparency.
Healthcare enforcement
Healthcare enforcement
DOL’s PBM Transparency Proposal Is Now Drawing a Scope Fight
DOL’s proposed PBM disclosure rule is still not final, but the comment period is closed and the real fight is now over scope, audit visibility, and how much compensation detail self-insured plan fiduciaries may ultimately receive.
Healthcare enforcement
CMS Simplified Medicare Advantage Stars for 2027. The Incentive Story Matters More.
The final rule narrows the Star Ratings framework, preserves the historical reward factor, and adds a new future behavioral health measure — a mix that matters for Medicare Advantage leaders, quality teams, and finance executives.
FDA Oversight Risk
Novo vs. Hims, Part II: Enforcement Didn’t End the Story — It Rewired the Channel
Hims’ collaboration with Novo and its move away from mass advertising of compounded GLP-1s suggests a tighter distribution lane: platform participation continues, but more explicitly aligned to FDA-approved products and individualized “clinically necessary” exceptions.